Novartis marks 30 year anniversary in transplantation and reinforces continued ... MarketWatch This global, Phase IV study, the largest ever in de novo kidney transplantation, is designed to evaluate the short- and long-term benefits of Certican plus low dose CNIs in kidney transplantation. The study of more than 2,000 ... Early vs delayed ... |
